American Society of Hirudotherapy

Dry Eye Syndrome

Investigational use for dry eye disease; no clinical study of leech therapy was identified, and the proposed meibomian-gland mechanism is hypothetical.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 17, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for dry eye disease. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for dry eye is investigational.
What evidence exists?
Tier C (investigational). No clinical study of leech therapy for dry eye disease was identified in the literature searches; a previously cited pilot study could not be verified and was removed. There are no randomized controlled trials. Evidence-based interventions include artificial tears, cyclosporine ophthalmic, lifitegrast, punctal plugs, warm compresses, and meibomian-gland-directed treatments — all supported by RCTs and remain first-line.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment (peri-orbital location)
  • Bruising and tenderness near the temple and brow for 5 to 10 days
  • Itching and irritation at bite sites near sensitive periocular skin
  • Local skin infection or, rarely, Aeromonas infection
  • Catastrophic harm if leech is mistakenly applied to the eyelid, conjunctiva, or orbit (NEVER do this)
  • Allergic reaction to leech saliva (uncommon)
  • Small bite marks that usually fade over weeks to months (rarely a pale spot stays longer)
Who should not consider this
  • Patients on blood thinners (anticoagulants such as warfarin, DOACs or heparin)
  • Patients with hemophilia or other bleeding disorders
  • Patients with anemia
  • Patients with recent ocular surgery (<3 months) or active eye infection
  • Patients with active blepharitis with infection
  • Patients considering this instead of an ophthalmology workup for severe or worsening dry eye
What to ask your clinician
  • Have I been evaluated by ophthalmology for underlying causes (Sjogren syndrome, meibomian dysfunction, neurotrophic dryness)?
  • Have I completed adequate trials of artificial tears, cyclosporine, lifitegrast, and warm compresses?
  • What evidence supports leech therapy for dry eye specifically?
  • How will leeches be kept off the eyelid, conjunctiva, and orbit?
  • What is the realistic chance of benefit, and for how long?
  • What is the practitioner's experience and Aeromonas-prevention plan?
  • What is the cost?
When to seek urgent care
  • Sudden severe eye pain or vision change
  • Spreading redness or pus near the eye (orbital cellulitis)
  • Bleeding from a bite site lasting more than 24 to 48 hours
  • Fever above 38.0 C / 100.4 F or chills
  • Hives, throat tightness, or breathing difficulty

What this does NOT mean

  • This is not FDA-cleared for dry eye disease.
  • With no clinical study identified, there is no evidence that leech therapy works better than placebo for dry eye.
  • Mechanism rationale (meibomian anti-inflammation) does NOT establish clinical efficacy.
  • Leech therapy is not a substitute for ophthalmologic evaluation or evidence-based topical therapy.
  • Any short-term symptom improvement reported anecdotally does not predict durable benefit.

Clinical Profile

Category
Ophthalmologic
ICD-10
H04.121, H04.122, H04.123, H04.129
Safety tier
Medium

Evidence Summary

No clinical study of leech therapy for dry eye syndrome was identified in PubMed, Europe PMC, Crossref, ClinicalTrials.gov, the Baskova and Isakhanyan 2004 monograph, or Russian-, German- and Ayurvedic-term searches; the rationale is hypothetical only. The hypothesized mechanism involves reduction of meibomian gland inflammation via systemic anti-inflammatory effects of absorbed salivary peptides, but this has not been demonstrated on validated outcomes such as OSDI or Schirmer testing. Leeches must NEVER be placed on the eyelid. No clinical evidence was identified, so leech therapy cannot be recommended over standard interventions (artificial tears, cyclosporine, lifitegrast, punctal plugs) and should be reserved, if used, for research settings under ophthalmologist supervision.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Recent (<3 months) eye surgery
  • Active conjunctivitis or blepharitis with infection

Related Conditions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.